文献速递泌尿生殖技术与安全PETCT

两种PET示踪剂对前列腺切除术后生化复发挽救性放疗计划的影响

18F-Fluciclovine or 68Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial.
PubMed 文献 · Radiology · 2026-01-01

本研究为EMPIRE-2试验的二次分析,纳入140例前列腺切除术后生化复发患者,随机接受18F-fluciclovine或68Ga-PSMA-11 PET/CT指导挽救性放疗。结果显示两种示踪剂均导致显著的放疗决策改变,但二者之间无统计学差异。

要点

  • 68Ga-PSMA-11总体放疗决策改变率为42%,18F-fluciclovine为29%,二者差异无统计学意义。
  • 在决定接受放疗的患者中,18F-fluciclovine的照射野或加量改变率(72%)高于68Ga-PSMA-11(54%)。
  • 两种PET示踪剂均可用于指导前列腺切除术后生化复发的精准放疗规划。

核心结论

  • 18F-fluciclovine和68Ga-PSMA-11 PET/CT指导挽救性放疗均可导致实质性治疗决策改变,但两种示踪剂之间无决策改变率的差异。
  • 在最终决定接受挽救性放疗的患者中,18F-fluciclovine PET/CT导致的治疗野或加量改变比68Ga-PSMA-11 PET/CT更常见(P = .046)。

研究设计与样本

  • 前瞻性随机对照试验EMPIRE-2的二次分析,研究时间为2019年5月至2023年5月。
  • 共纳入140例前列腺切除术后PSA可检测的患者,年龄范围47-83岁,1:1随机分配至18F-fluciclovine组(平均年龄63岁±8,中位放疗前PSA 0.27 ng/mL)或68Ga-PSMA-11组(平均年龄65岁±8,中位放疗前PSA 0.35 ng/mL)。
  • 6例参与者在PET/CT前退出试验,其中18F-fluciclovine组5例、68Ga-PSMA-11组1例。
  • 采用Clopper-Pearson二项法评估两组在PET前后是否给予放疗及照射野决策的变化。
  • 临床试验注册号:NCT03762759。

诊断标准与关键数值

  • 18F-fluciclovine组总体挽救性放疗决策改变率为29%(19/65),P < .001。
  • 68Ga-PSMA-11组总体挽救性放疗决策改变率为42%(29/69),P < .001。
  • 两组间总体决策改变率无统计学差异(P = .12)。
  • 在最终决定接受挽救性放疗的参与者中,18F-fluciclovine组治疗野或加量改变率为72%(43/60),P < .001。
  • 68Ga-PSMA-11组治疗野或加量改变率为54%(33/61),P < .001;18F-fluciclovine组高于68Ga-PSMA-11组(P = .046)。

临床应用与阅片要点

  • 前列腺切除术后生化复发患者的放疗规划前,18F-fluciclovine与68Ga-PSMA-11 PET/CT均可作为指导工具。
  • 18F-fluciclovine PET/CT可能对具体照射野和加量区域的选择影响更大,报告时应重点描述可疑复发病灶的解剖位置。
  • 单凭两种示踪剂之间总体决策改变率相近,不能认为二者在放疗规划中可完全互换。

局限性

  • 本研究为EMPIRE-2试验的二次分析,结局指标为决策改变而非生存或生化控制等临床终点。
  • 试验中存在6例随机后退出的参与者,可能对结果产生一定影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background PET with gallium 68 (68Ga) prostate-specific membrane antigen (PSMA)-11 and fluorine 18 (18F) fluciclovine has influenced salvage radiation therapy (sRT) planning in postprostatectomy biochemical recurrence. Purpose To assess the comparative impact of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT on sRT changes in postprostatectomy biochemical recurrence. Materials and Methods In this secondary analysis of a prospective randomized controlled trial, men with detectable prostate-specific antigen (PSA) levels after prostatectomy were randomly assigned to undergo 18F-fluciclovine PET/CT (arm A) or 68Ga-PSMA-11 PET/CT (arm B) between May 2019 and May 2023. The Clopper-Pearson binomial method was used to evaluate decision changes on whether to offer radiation therapy (RT) and to which field (with or without boost) between the pre- and post-PET time points in each arm, and to compare decision changes between the arms. Results A total of 140 eligible participants (age range, 47-83 years) were randomly assigned 1:1 to arm A (mean age, 63 years ± 8 [SD]; median pre-RT PSA level, 0.27 ng/mL) or to arm B (mean age, 65 years ± 8; median pre-RT PSA, 0.35 ng/mL). Six participants (five in the 18F-fluciclovine group and one in the 68Ga-PSMA-11 group) withdrew from the trial before undergoing PET/CT. Overall sRT decision changes occurred in 19 of 65 participants (29%) in arm A (P < .001) and 29 of 69 participants (42%) in arm B (P < .001), but there was no evidence of a difference between arms (P = .12). Among participants for whom the final decision was to offer them sRT, treatment field (and/or boost) changes occurred in 43 of 60 participants (72%) in arm A (P < .001) and 33 of 61 participants (54%) in arm B (P < .001) and were more likely with 18F-fluciclovine PET/CT than with 68Ga-PSMA-11 PET/CT (P = .046). Conclusion In postprostatectomy biochemical recurrence, the use of 18F-fluciclovine and 68Ga-PSMA-11 for PET/CT-guided sRT planning resulted in substantial treatment decision changes, but there was no difference in the likelihood of a decision change between the two radiotracers. Treatment field (and/or boost) changes were more likely with 18F-fluciclovine PET/CT than with 68Ga-PSMA-11 PET/CT. Clinical trial registration no. NCT03762759 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Iravani in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Abiodun-Ojo, Jani, Goyal, et al. 18F-Fluciclovine or 68Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial. Radiology. 2026. PMID: 42377125. doi:10.1148/radiol.251874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。